Evotec Aktiengesellschaft – Product Pipeline Review – H2 2011 by GlobalMarketsDirect

VIEWS: 5 PAGES: 174

More Info
									Evotec Aktiengesellschaft – Product Pipeline Review –
                      H2 2011
                                                                                          Reference Code: GMDHC01701CDB

                                                                                                 Publication Date: NOV 2011




Evotec Aktiengesellschaft – Product Pipeline Review – H2 2011                               GMDHC01701CDB / Published NOV 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                 Page(1)
Evotec Aktiengesellschaft – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 7
      List of Figures .................................................................................................................................................................................................... 9
Evotec Aktiengesellschaft Snapshot ........................................................................................................................................................................10
      Evotec Aktiengesellschaft Overview ..................................................................................................................................................................10
      Key Information .................................................................................................................................................................................................10
      Key Facts ..........................................................................................................................................................................................................10
Evotec Aktiengesellschaft – Research and Development Overview .........................................................................................................................11
      Key Therapeutic Areas ......................................................................................................................................................................................11
Evotec Aktiengesellschaft – Pipeline Review ...........................................................................................................................................................14
      Pipeline Products by Stage of Development ......................................................................................................................................................14
      Evotec Aktiengesellschaft – Pipeline Products Glance ......................................................................................................................................15
      Evotec Aktiengesellschaft Clinical Stage Pipeline Products ...............................................................................................................................15
            Phase II Products/Combination Treatment Modalities .................................................................................................................................15
            Phase I Products/Combination Treatment Modalities ..................................................................................................................................16
      Evotec Aktiengesellschaft–Early Stage Pipeline Products .................................................................................................................................17
            Pre-Clinical Products/Combination Treatment Modalities ............................................................................................................................17
            Discovery Products/Combination Treatment Modalities ..............................................................................................................................18
Evotec Aktiengesellschaft – Drug Profiles................................................................................................................................................................19
      B1 Antagonists ..................................................................................................................................................................................................19
            Product Description ....................................................................................................................................................................................19
            Mechanism of Action...................................................................................................................................................................................19
            R&D Progress .............................................................................................................................................................................................19
      BACE Inhibitors.................................................................................................................................................................................................20
            Product Description ....................................................................................................................................................................................20
            Mechanism of Action...................................................................................................................................................................................20
            R&D Progress .............................................................................................................................................................................................20
      DG3173 ............................................................................................................................................................................................................21
            Product Description ....................................................................................................................................................................................21
            Mechanism of Action...................................................................................................................................................................................21
            R&D Progress .............................................................................................................................................................................................21
      Drug for Anemia ................................................................................................................................................................................................22
            Product Description ....................................................................................................................................................................................22
            Mechanism of Action...................................................................................................................................................................................22
            R&D Progress .............................................................................................................................................................................................22
      EVT 103 ............................................................................................................................................................................................................23
            Product Description ....................................................................................................................................................................................23
            Mechanism of Action...................................................................................................................................................................................23
            R&D Progress .............................................................................................................................................................................................23
      EVT 302 ............................................................................................................................................................................................................24
            Product Description ....................................................................................................................................................................................24
            Mechanism of Action...................................................................................................................................................................................24
            R&D Progress .............................................................................................................................................................................................24
      EVT 302 + Nicotine Replacement .....................................................................................................................................................................25
            Product Description ....................................................................................................................................................................................25
            Mechanism of Action...................................................................................................................................................................................25




Evotec Aktiengesellschaft – Product Pipeline Review – H2 2011                                                                                              GMDHC01701CDB / Published NOV 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                                                                                                               Page(2)
Evotec Aktiengesellschaft – Product Pipeline Review



           R&D Progress .............................................................................................................................................................................................25
     EVT 401 ............................................................................................................................................................................................................27
           Product Description ....................................................................................................................................................................................27
           Mechanism of Action...................................................................................................................................................................................27
           R&D Progress .............................................................................................................................................................................................27
     EVT501 .............................................................................................................................................................................................................28
           Product Description ....................................................................................................................................................................................28
           Mechanism of Action...................................................................................................................................................................................28
           R&D Progress .............................................................................................................................................................................................28
     Insulin Sensitizers .............................................................................................................................................................................................29
           Product Description ....................................................................................................................................................................................29
           Mechanism of Action...................................................................................................................................................................................29
           R&D Progress .............................................................................................................................................................................................29
     Kv1.3 inhibitors .................................................................................................................................................................................................30
           Product Description ....................................................................................................................................................................................30
           Mechanism of Action...................................................................................................................................................................................30
           R&D Progress .............................................................................................................................................................................................30
     Orexin 2 ............................................................................................................................................................................................................31
           Product Description ....................................................................................................................................................................................31
           Mechanism of Action...................................................................................................................................................................................31
           R&D Progress .............................................................................................................................................................................................31
     P2X3 and P2X2/3 Antagonist ............................................................................................................................................................................32
           Product Description ....................................................................................................................................................................................32
           Mechanism of Action...................................................................................................................................................................................32
           R&D Progress .............................................................................................................................................................................................32
     PDE10a inhibitors .............................................................................................................................................................................................33
           Product Description ....................................................................................................................................................................................33
           Mechanism of Action...................................................................................................................................................................................33
           R&D Progress .............................................................................................................................................................................................33
     Serine Racemase Inhibitors ..............................................................................................................................................................................34
           Product Description ....................................................................................................................................................................................34
           Mechanism of Action...................................................................................................................................................................................34
           R&D Progress .............................................................................................................................................................................................34
     VR1 Antagonist .................................................................................................................................................................................................35
           Product Description ....................................................................................................................................................................................35
           Mechanism of Action...................................................................................................................................................................................35
           R&D Progress .............................................................................................................................................................................................35
Evotec Aktiengesellschaft – Pipeline Analysis .........................................................................................................................................................36
     Evotec Aktiengesellschaft – Pipeline Products by Therapeutic Class ................................................................................................................36
     Evotec Aktiengesellschaft - Pipeline Products By Target ...................................................................................................................................38
     Evotec Aktiengesellschaft – Pipeline Products by Route of Administration ........................................................................................................40
     Evotec Aktiengesellschaft – Pipeline Products by Molecule Type ......................................................................................................................41
Evotec Aktiengesellschaft – Recent Pipeline Updates ............................................................................................................................................42
Evotec Aktiengesellschaft - Dormant Projects..........................................................................................................................................................44
Evotec Aktiengesellschaft - Discontinued Pipeline Products ....................................................................................................................................45
     Discontinued Pipeline Product Profiles ..............................................................................................................................................................45
           EVT 302 .....................................................................................................................................................................................................45
           EVT 101 .....................................................................................................................................................................................................45




Evotec Aktiengesellschaft – Product Pipeline Review – H2 2011                                                                                              GMDHC01701CDB / Published NOV 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                                                                                                               Page(3)
Evotec Aktiengesellschaft – Product Pipeline Review



           EVT-201 .....................................................................................................................................................................................................45
           ND1251 ......................................................................................................................................................................................................46
           ND7001 ......................................................................................................................................................................................................46
           REN-1654 ...................................................................................................................................................................................................46
Evotec Aktiengesellschaft – Company Statement ....................................................................................................................................................47
Evotec Aktiengesellschaft – Locations And Subsidiaries..........................................................................................................................................48
     Head Office .......................................................................................................................................................................................................48
     Other Locations & Subsidiaries .........................................................................................................................................................................48
Recent Developments .............................................................................................................................................................................................50
           May 31, 2005: Renovis Enters In To Collaboration And License Agreement With Pfizer To Develop VR1 Antagonists ...............................50
           Jun 29, 2009: Evotec Announces The Successful Completion Of The First Phase I Study With EVT 401 ...................................................50
           Jul 28, 2008: ND 7001 Evotec Discontinued ...............................................................................................................................................51
           Jun 28, 2005: Neuro3d Initiates Depression Trials With ND7001 ................................................................................................................51
           Mar 28, 2008: Evotec's EVT 101 Shows To Penetrate The Brain In Man And To Modulate Brain Activity During The Performance Of
           Cognitive Tasks ..........................................................................................................................................................................................52
           Oct 27, 2008: Evotec Reports Phase I Safety Data From Tyramine Interaction Study With EVT 302 ..........................................................52
           Feb 26, 2009: DeveloGen Reports Positive Phase I Clinical Trial Results for DG3173................................................................................53
           Aug 25, 2005: Renovis Announces Results Of Phase II Study Of Ren-1654 For The Treatment Of Sciatica...............................................53
           Mar 24, 2004: Evotec Neurosciences Licence NMDA Receptor NR2B Subunit Selective Antagonists From Roche ....................................54
           Mar 22, 2007: Evotec Initiates Its First Phase I Clinical Study With EVT 302 ..............................................................................................55
           Sep 21, 2006: Evotec Initiates Phase II Clinical Trial With EVT 201 For The Treatment Of Insomnia ..........................................................55
           Oct 20, 2005: Evotec Reports Positive Results Of Repositioning Clinical Trial On CNS Compound ............................................................56
           Nov 18, 2009: Evotec Wins German Government Research Grant .............................................................................................................56
           May 18, 2011: Evotec And Roche Announce Phase II Study With NR2B Sub-Type Selective NMDA Antagonist In Treatment-Resistant
           Depression Voluntarily Terminated .............................................................................................................................................................57
           Nov 17, 2006: Evotec Initiates Second Phase II Clinical Trial With Insomnia Drug EVT 201 .......................................................................57
           Oct 16, 2006: Evotec Reports Positive Top-Line Results In Phase II Study With EVT 201 In Elderly Insomniacs With Daytime Sleepiness 58
           Jul 15, 2004: Neuro3d Receives Support From ANVAR For Ongoing Clinical Development of Its Antidepressant ND1251 ........................58
           Nov 14, 2005: Evotec Announces Initiation Of Phase I Clinic Trial With EVT 101 .......................................................................................59
           Apr 14, 2008: Evotec Reports Results Of Phase II Proof-Of-Concept Study With EVT 302 .........................................................................60
           Sep 11, 2008: Evotec Reports Start Of Phase II Proof-Of-Concept Quit Rate Study With EVT 302 And Results Of Craving Study .............60
           Mar 11, 2010: Evotec Completes Clinical Part Of First Phase I Study Of EVT 103 ......................................................................................61
           Mar 11, 2010: Evotec Reports Progress Of EVT 101 In Treatment-Resistant Depression ...........................................................................61
           Nov 09, 2008: Evotec Reports Start of Phase II Proof-of-Concept Quit Rate Study with EVT 302 and Results of Craving Study ................61
           Oct 09, 2008: Evotec Announces Phase I Initiation With P2X7 Antagonist ..................................................................................................62
           Mar 09, 2009: Evotec And Roche Enters In To Agreement To Develop EVT 101 In Phase II ......................................................................62
           Oct 08, 2008: DeveloGen Announces Completion Of A Phase I Clinical Trial Of DG3173, A Novel Somatostatin Analogue For The
           Treatment Of Acromegaly ...........................................................................................................................................................................63
           Sep 08, 2009: Evotec AG Announces Top-Line Results Of Phase Ib Study With EVT 101 .........................................................................64
           Sep 08, 2009: Evotec Starts Phase I With EVT 103, An NR2B-Selective NMDA Receptor Antagonist ........................................................64
           Jun 08, 2006: Evotec Announces Positive Phase I/II Clinical Trial Results With Insomnia Treatment EVT 201 ...........................................65
           an 07, 2008: Evotec Starts Phase II In Smoking Cessation With EVT 302 ..................................................................................................65
           Jan 07, 2008: Phase I Safety And Tolerability Study With EVT 302 Successfully Completed ......................................................................66
           Sep 05, 2007: Evotec Reports Details Of The Positive Proof-Of-Concept Phase II Study In Insomnia With EVT 201..................................66
           May 05, 2008: Evotec Completes Acquisition of Renovis ............................................................................................................................67
           Jun 04, 2007: Evotec Reports Positive Proof-Of-Concept Top-Line Results With Insomnia Drug Candidate EVT 201 ................................68
           Feb 02, 2010: Evotec And Vifor Pharma Sign Major Cooperation Agreement .............................................................................................68
           Jan 02, 2005: Renovis Announces Completion Of Enrollment In Phase II Trial Of REN-1654 In Post-Herpetic Neuralgia (PHN) ................69
           Aug 01, 2008: Evotec Announces Initiation Of Phase I Clinical Trial Of VR1 Antagonist Under Partnership With Pfizer Inc. .......................69




Evotec Aktiengesellschaft – Product Pipeline Review – H2 2011                                                                                            GMDHC01701CDB / Published NOV 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                                                                                                             Page(4)
Evotec Aktiengesellschaft – Product Pipeline Review



           Jul 01, 2010: Evotec Initiates Phase II Study Of EVT 101 In Treatment-Resistant Depression Patients ......................................................70
Financial Deals Landscape......................................................................................................................................................................................71
     Evotec Aktiengesellschaft, Deals Summary.......................................................................................................................................................71
Evotec Aktiengesellschaft, Pharmaceuticals & Healthcare, Deal Details ..................................................................................................................77
     Asset Transactions............................................................................................................................................................................................77
           Evotec Acquires Zebrafish Screening Operations From Summit .................................................................................................................77
           Evotec Acquires NMR Screening Assets And Intellectual Property From Combinature ....................................
								
To top